Comparing Trospectomycin and Clindamycin for Infections
Author Information
Author(s): Ashwin Chatwani, Mark Martens, Jorge Blanco, Stanley Gall, Kira Przybylko, Charles P. Wajszczuk, Dana Nickens
Primary Institution: Temple University School of Medicine
Hypothesis
Is trospectomycin sulfate as effective and safe as clindamycin phosphate, both with aztreonam, for treating obstetric and gynecologic infections?
Conclusion
Trospectomycin was as effective as clindamycin when both were combined with aztreonam in treating obstetric and gynecologic infections.
Supporting Evidence
- The cure rate for the trospectomycin group was 91.8%, while for the clindamycin group it was 88.4%.
- Both groups had similar adverse events.
- Patients were followed for clinical responses and side effects.
Takeaway
This study looked at two antibiotics to see which one works better for infections after surgery. They found that both worked about the same.
Methodology
A double-blind, multicenter, prospective randomized study with 579 patients receiving either trospectomycin or clindamycin, both with aztreonam.
Potential Biases
Potential bias from the exclusion of patients with other infections or prior antibiotic use.
Limitations
Patients with other infections or who had taken antibiotics recently were excluded, which may limit generalizability.
Participant Demographics
Patients were hospitalized women, 16 years or older, with pelvic cellulitis or endometritis.
Statistical Information
P-Value
0.218
Statistical Significance
p=0.218
Want to read the original?
Access the complete publication on the publisher's website